CLINICIQ DIAGNOSTIC REPORT - SAMPLE

Equipment ROI snapshot

Models the payback period and revenue potential for a specific piece of equipment.

Prepared for	**Report ID**	**Reviewed by**
Westfield Family Medicine 4 providers - Family medicine	CIQ-2024-1184 March 14, 2024	Anthonette Sparman, MD Founder, ClinicIQ

SAMPLE REPORT. Names, numbers, and findings are illustrative. Your delivered report is built from your own intake responses and benchmarked against your specialty + region.

EXECUTIVE SUMMARY

At 8 procedures/week, the equipment pays back in 14 months and clears $112K in year 2.

The analysis below benchmarks your practice against peers in your specialty and region and quantifies the dollar impact of each opportunity. Findings are ranked by net contribution, then by time-to-launch. Every dollar figure carries a methodology citation in the appendix.

KEY FINDINGS

Scenario	Break-even (months)	Year-2 contribution
Downside (4 procedures/wk)	**22 mo**	$41,200
Base (8 procedures/wk)	**14 mo**	$112,400
Upside (12 procedures/wk)	**9 mo**	$184,600
Lease vs. buy (5-yr after-tax)	**Buy +$28K**	if utilization >= base

IN YOUR DELIVERED REPORT

- 12 / 24 / 36-month revenue model for the equipment with downside / base / upside scenarios

  Assumes: *Volume ramp: downside = 50% of your estimate, base = 100%, upside = 130%; reimbursement held flat (no annual rate increase assumed).*

- Break-even patient volume per week + months-to-payback in each scenario

  Assumes: *Payback = (purchase price + financing cost + training) ÷ monthly contribution margin; ignores tax shield until the lease-vs-buy view.*

- Lease vs. buy comparison with after-tax cash flow over 36 months

  Assumes: *Federal corporate rate 21% (adjustable); financing terms use your reported quote or a default 6-yr 8.5% APR if none.*

- CPT codes + per-procedure reimbursement assumptions + payer coverage notes

  Assumes: *Medicare baseline × your commercial multiplier; commercial coverage flagged for top 4 national payers only.*

- 1-page partner/lender summary (PDF) with the recommendation and the break-even chart

Assumes: *Designed to support a 5-minute capital decision conversation, not to replace a full CFO review.*

METHODOLOGY & SOURCES

1. We model three scenarios (downside, base, upside) using realistic ramp curves, not vendor projections.

2. Lease vs. buy compares after-tax cash flow using a 21% federal corp rate (adjustable) and your assumed financing terms.

3. Reimbursement assumptions cite Medicare baselines and adjust for commercial multiplier in your region.

Benchmarks: MGMA DataDive 2023, CMS Physician Fee Schedule (current year), regional peer panel (n=42). All recovery estimates are directional and intentionally conservative.

Physician-reviewed - Anthonette Sparman, MD. This report is advisory and does not constitute legal, billing-compliance, or investment advice. Recovery estimates assume your reported volume and payer mix; actual results vary by execution.